164 related articles for article (PubMed ID: 21931503)
1. Use of capecitabine in management of early colon cancer.
Hameed H; Cassidy J
Cancer Manag Res; 2011; 3():295-9. PubMed ID: 21931503
[TBL] [Abstract][Full Text] [Related]
2. The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation.
Pandor A; Eggington S; Paisley S; Tappenden P; Sutcliffe P
Health Technol Assess; 2006 Nov; 10(41):iii-iv, xi-xiv, 1-185. PubMed ID: 17049138
[TBL] [Abstract][Full Text] [Related]
3. Redefining adjuvant chemotherapy in patients with stage III colon cancer: X-ACT trial.
Glen H; Cassidy J
Expert Rev Anticancer Ther; 2008 Apr; 8(4):547-51. PubMed ID: 18402521
[TBL] [Abstract][Full Text] [Related]
4. Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial.
Cassidy J; Douillard JY; Twelves C; McKendrick JJ; Scheithauer W; Bustová I; Johnston PG; Lesniewski-Kmak K; Jelic S; Fountzilas G; Coxon F; Díaz-Rubio E; Maughan TS; Malzyner A; Bertetto O; Beham A; Figer A; Dufour P; Patel KK; Cowell W; Garrison LP
Br J Cancer; 2006 Apr; 94(8):1122-9. PubMed ID: 16622438
[TBL] [Abstract][Full Text] [Related]
5. Capecitabine versus bolus fluorouracil plus leucovorin (folinic acid) as adjuvant chemotherapy for patients with Dukes' C colon cancer : economic evaluation in an Italian NHS setting.
Di Costanzo F; Ravasio R; Sobrero A; Bertetto O; Vinante O; Luppi G; Labianca R; Amadori D; Barone C; Carlo Merlano M; Longo F; Mansueto G; Antonuzzo L; Gasperoni S
Clin Drug Investig; 2008; 28(10):645-55. PubMed ID: 18783303
[TBL] [Abstract][Full Text] [Related]
6. Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.
Schmoll HJ; Tabernero J; Maroun J; de Braud F; Price T; Van Cutsem E; Hill M; Hoersch S; Rittweger K; Haller DG
J Clin Oncol; 2015 Nov; 33(32):3733-40. PubMed ID: 26324362
[TBL] [Abstract][Full Text] [Related]
7. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer.
Haller DG; Tabernero J; Maroun J; de Braud F; Price T; Van Cutsem E; Hill M; Gilberg F; Rittweger K; Schmoll HJ
J Clin Oncol; 2011 Apr; 29(11):1465-71. PubMed ID: 21383294
[TBL] [Abstract][Full Text] [Related]
8. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials.
Schmoll HJ; Twelves C; Sun W; O'Connell MJ; Cartwright T; McKenna E; Saif M; Lee S; Yothers G; Haller D
Lancet Oncol; 2014 Dec; 15(13):1481-1492. PubMed ID: 25456367
[TBL] [Abstract][Full Text] [Related]
9. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
10. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.
Twelves C; Boyer M; Findlay M; Cassidy J; Weitzel C; Barker C; Osterwalder B; Jamieson C; Hieke K;
Eur J Cancer; 2001 Mar; 37(5):597-604. PubMed ID: 11290435
[TBL] [Abstract][Full Text] [Related]
11. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients.
Schmoll HJ; Cartwright T; Tabernero J; Nowacki MP; Figer A; Maroun J; Price T; Lim R; Van Cutsem E; Park YS; McKendrick J; Topham C; Soler-Gonzalez G; de Braud F; Hill M; Sirzén F; Haller DG
J Clin Oncol; 2007 Jan; 25(1):102-9. PubMed ID: 17194911
[TBL] [Abstract][Full Text] [Related]
12. Oral capecitabine: bridging the Atlantic divide in colon cancer treatment.
Van Cutsem E; Verslype C; Tejpar S
Semin Oncol; 2005 Feb; 32(1):43-51. PubMed ID: 15726505
[TBL] [Abstract][Full Text] [Related]
13. Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial: overview of efficacy, safety, and cost-effectiveness.
Twelves CJ
Clin Colorectal Cancer; 2006 Nov; 6(4):278-87. PubMed ID: 17241512
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.
de Gramont A; Van Cutsem E; Schmoll HJ; Tabernero J; Clarke S; Moore MJ; Cunningham D; Cartwright TH; Hecht JR; Rivera F; Im SA; Bodoky G; Salazar R; Maindrault-Goebel F; Shacham-Shmueli E; Bajetta E; Makrutzki M; Shang A; André T; Hoff PM
Lancet Oncol; 2012 Dec; 13(12):1225-33. PubMed ID: 23168362
[TBL] [Abstract][Full Text] [Related]
15. Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study.
Twelves CJ; Butts CA; Cassidy J; Conroy T; Braud Fd; Diaz-Rubio E; Tabernero JM; Schoffski P; Figer A; Brunet R; Grossmann J; Sobrero AF; Van Cutsem EJ
Clin Colorectal Cancer; 2005 Jul; 5(2):101-7. PubMed ID: 16098250
[TBL] [Abstract][Full Text] [Related]
16. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.
Cassidy J; Tabernero J; Twelves C; Brunet R; Butts C; Conroy T; Debraud F; Figer A; Grossmann J; Sawada N; Schöffski P; Sobrero A; Van Cutsem E; Díaz-Rubio E
J Clin Oncol; 2004 Jun; 22(11):2084-91. PubMed ID: 15169795
[TBL] [Abstract][Full Text] [Related]
17. Commentary on a phase III trial of bevacizumab plus XELOX or FOLFOX4 for first-line treatment of metastatic colorectal cancer: the NO16966 trial.
Tyagi P; Grothey A
Clin Colorectal Cancer; 2006 Nov; 6(4):261-4. PubMed ID: 17241510
[TBL] [Abstract][Full Text] [Related]
18. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Van Cutsem E; Twelves C; Cassidy J; Allman D; Bajetta E; Boyer M; Bugat R; Findlay M; Frings S; Jahn M; McKendrick J; Osterwalder B; Perez-Manga G; Rosso R; Rougier P; Schmiegel WH; Seitz JF; Thompson P; Vieitez JM; Weitzel C; Harper P;
J Clin Oncol; 2001 Nov; 19(21):4097-106. PubMed ID: 11689577
[TBL] [Abstract][Full Text] [Related]
19. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study.
Rothenberg ML; Cox JV; Butts C; Navarro M; Bang YJ; Goel R; Gollins S; Siu LL; Laguerre S; Cunningham D
Ann Oncol; 2008 Oct; 19(10):1720-6. PubMed ID: 18550577
[TBL] [Abstract][Full Text] [Related]
20. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108.
Comella P; Natale D; Farris A; Gambardella A; Maiorino L; Massidda B; Casaretti R; Tafuto S; Lorusso V; Leo S; Cannone M
Cancer; 2005 Jul; 104(2):282-9. PubMed ID: 15948167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
